{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The effect of sildenafil on post-cardiac surgery acute kidney injury: a randomised controlled trial."
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In a double-blind, parallel-group randomised controlled trial, 129 adults at increased risk of AKI undergoing cardiac surgery at a single UK tertiary centre were randomised."
      },
      "Participants": {
        "score": 2,
        "evidence": "129 adults at increased risk of AKI undergoing cardiac surgery at a single UK tertiary centre."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either sildenafil citrate 12.5 mg intravenously over 150 minutes or a dextrose 5% placebo at the start of surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assessed the efficacy of intravenous sildenafil citrate in preventing acute kidney injury (AKI) in patients undergoing cardiac surgery with cardiopulmonary bypass."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was serum creatinine concentration measured at six time points up to 96 hours post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was stratified by procedure type and baseline estimated glomerular filtration rate, with allocation concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Patients, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between September 2015 and September 2018, 60 participants were randomised to sildenafil and 69 to placebo."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The intention-to-treat analysis showed no significant difference in serum creatinine between groups."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "mean difference: 0.88 \u03bcmol/L, 95% CI: -5.82 to 7.59, p = 0.797"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar, with no anaphylactic reactions reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ISRCTN18386427."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: British Heart Foundation and Leicester and Bristol National Institute for Health Research Cardiovascular Biomedical Research Units."
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}